News

Paul N. Staats, MD Takes the Helm at University of Maryland

Paul N. Staats, MD Takes the Helm at University of Maryland

Dr. Paul N. Staats, MD Named Chair of Pathology

Will serve as Chief of Pathology Service at UM Medical Center, Chief of Pathology and Laboratory Medicine at UM Medical System, and President of the University of Maryland Pathology Associates, PA

BALTIMORE / Dr. Paul N. Staats, MD, a distinguished expert in cytopathology and gynecologic pathology, has been appointed Chair of the Department of Pathology at the University of Maryland School of Medicine (UMSOM). His new role commenced on September 29, following an interim period that started in February when Dr. Sanford A. Stass stepped down from the position.

In his permanent position, Dr. Staats will manage a department consisting of 35 faculty members, 16 residents, and three fellows. They deliver clinical services to various institutions, including the University of Maryland Medical Center (Downtown and Midtown Campus), UM Rehabilitation and Orthopedic Institute, and UM Shore Regional Health. Furthermore, he will concurrently act as Chief of the Pathology Service at University of Maryland Medical Center (UMMC), in addition to being President of the University of Maryland Pathology Associates, PA, overseeing community faculty practices and independent clinical laboratories.

Dr. Staats will also serve as the Chief of Pathology and Laboratory Medicine for the University of Maryland Medical System (UMMS), coordinating pathology services across 12 hospitals and over 150 clinical locations.

"Since joining our faculty, Dr. Staats has initiated several projects aimed at modernizing our clinical and anatomical pathology capabilities while promoting the development of future practitioners and researchers," stated Dr. Mark T. Gladwin, MD, Vice President for Medical Affairs at the University of Maryland, Baltimore. "His dedication to enhancing diagnostic practices and implementing innovative solutions in patient care makes him ideally suited to advance the Department of Pathology's core missions: research, education, clinical excellence, and community service."

"Dr. Staats is taking on this vital leadership role during an exciting time for UMMS, UMSOM, and the field of pathology," commented Dr. Mohan Suntha, MD, MBA, President and CEO of UMMS. "His skill in building strong clinical and research collaborations will propel us forward in delivering excellent diagnostic services, setting the stage for new clinical practices and discoveries."

Dr. Staats is recognized for his significant contributions, enhancing UMMC's reputation nationally in clinical innovation according to Dr. Bert W. O'Malley, MD, President and CEO of UMMC. "Having a top-tier investigator and committed educator leading our team will bolster our development of emerging pathology technologies and accelerate advancements in patient care. Dr. Staats embodies the leadership necessary to fulfill this vision."

Academic Background and Leadership

Dr. Staats earned a Bachelor of Science in Chemistry from Yale University and his MD from SUNY Upstate Medical University. He completed his training in anatomical and clinical pathology, cytopathology, and gynecologic pathology at Massachusetts General Hospital and Harvard Medical School before becoming an Assistant Professor of Pathology at UMSOM in 2009.

Prior to his interim chair position, Dr. Staats held several vital roles, including director of anatomic pathology operations, director of cytopathology, and director of the cytopathology fellowship program at UMMC. His work has focused on enhancing laboratory efficiency and integrating pathology services across different hospital campuses. He has also significantly revamped electronic medical record systems and redesigned the anatomical pathology workflow at UMMC.

During his tenure as Interim Chair, Dr. Staats forged partnerships with UM Pathology Associates and expanded outpatient laboratory services. His leadership has strengthened financial operations and boosted departmental efficiencies. He also takes on the vital role of Medical Director for the UMMS Epic Beaker laboratory system transition project.

Research Contributions

Dr. Staats is a prominent scholar with 56 peer-reviewed publications and 12 book chapters to his name. Focused on enhancing diagnostic practices, his research investigates the morphological criteria for malignancy identification and aims to elevate laboratory quality and efficiency practices.

He is a part of the Hormone Responsive Cancers Program within the University of Maryland Marlene and Stewart Greenebaum Cancer Center, collaborating with various researchers to innovate diagnosis, treatment, and prevention strategies for cancers, particularly breast, gynecologic, and prostate cancers.

Professional Recognition

Dr. Staats has held various leadership roles including past president of the Association of Directors of Anatomic and Surgical Pathology and current chair of the Fellowship Directors Committee where he is working to nationalize pathology fellowship recruitment. Additionally, he serves on the editorial boards of the Journal of the American Society of Cytopathology and the International Journal of Gynecologic Pathology.

A dedicated educator, Dr. Staats has received the Harlan I. Firminger, M.D. Faculty Teaching Prize in Pathology twice and was honored as Best Attending Pathologist Teacher by residents, reflecting his commitment to teaching and mentorship. Recently, he was awarded the Margaret Grimes Distinguished Achievement Award in Graduate Medical Education for his pivotal work on pathology fellowship matching.

"Having spent my career at the University of Maryland, I owe much to the mentorship I've received and the supportive environment here. I am thrilled to give back in these leadership roles and guide the Department of Pathology towards new heights in our academic mission," commented Dr. Staats.

"I am excited about my role as UMMS Chief of Pathology. Collaborating closely with the University and the Medical System is vital for advancing our patient care standards," Dr. Staats added.

About the University of Maryland School of Medicine

The University of Maryland School of Medicine, founded in 1807, stands as the first public medical school in the U.S. Today, it is recognized as one of the most rapidly growing biomedical research institutions globally with nearly $500 million in research funding. With a rich roster of over 3,000 faculty members and 46 departments, centers, and institutes, it excels in managing critical health challenges like obesity, cancer, and heart disease. Recently ranked #12 among public medical schools, the School is at the forefront of new AI and health computing initiatives and collaborates with the University of Maryland BioPark to spearhead innovations in medical technology and bioengineering.

Frequently Asked Questions

Who is Dr. Paul N. Staats, MD?

Dr. Paul N. Staats is a nationally recognized expert in cytopathology and gynecologic pathology, appointed as Chair of Pathology at the University of Maryland School of Medicine.

What roles will Dr. Staats undertake as Chair?

He will oversee the Department of Pathology, serve as Chief of the Pathology Service at UM Medical Center, and coordinate pathology services across the UM Medical System.

What are Dr. Staats's objectives in his new role?

His primary objectives include improving diagnostic practices and fostering innovation to enhance clinical and research collaborations.

What academic background does Dr. Staats have?

Dr. Staats holds a BS from Yale University and an MD from SUNY Upstate Medical University, with advanced training from renowned institutions.

Why is the University of Maryland School of Medicine notable?

It is the first public medical school in the U.S., known for its significant research contributions and efforts to address critical health challenges.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Aurora Innovation Faces Legal Heat Amid Delays

Updated Category News Views 76

Production Snags at Aurora Innovation Ah, investing – not for the faint-hearted. One day you're riding high, the next you're scraping by, and Aurora Innovation's (NASDAQ:AUR) investors just hit a rough patch. The autonomous trucking darling announced unexpected delays in its delivery schedule, sending shockwaves through its stock price and shaking investor confidence....

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 92

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
Paris Baguette Pioneers Drive-Thru in Oklahoma

Updated Category News Views 88

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Continue Reading
Mynd.ai Alters ADS Ratio Affecting Share Dynamics

Updated Category News Views 82

Analyzing Mynd.ai's ADS Ratio Tweak When Mynd.ai decides to shake things up with the American Depositary Shares (ADS) ratio, it's like they're throwing a curveball straight at Wall Street. Listen up, this isn't just a deck shuffle—it's a fundamental tweak that could play a big role in the stock’s perceived value. Starting December 7, 2027, one ADS will leap from...

Continue Reading
James Hardie Joins S&P MidCap 400; Roku Acquired

Updated Category News Views 80

A Shift in the MidCap 400: What's Up? Well, wouldn’t you know it, James Hardie Industries is making waves as it steps into the S&P MidCap 400. This move happens because Fox Corp. has nabbed Roku in a deal worthy of some popcorn. Come November 11, when the trading floor wakes up, James Hardie will be in and Roku will be out. Pretty neat switcheroo if you ask me. Inside...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 100

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
Madrigal Faces Legal Scrutiny Amid Whistleblower Claims

Updated Category News Views 204

The Storm Brewing Over Madrigal Pharmaceuticals Well, folks, here we are smack dab in the middle of another roller-coaster ride in the biotech sector, and it ain't pretty. Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is in hot water with some serious allegations thrown their way. The company is now under investigation by Kessler Topaz Meltzer & Check, LLP, a top-notch...

Continue Reading
Nemazee Fellowship Advances Clemency and Justice Reform

Updated Category News Views 96

Nemazee Fellowship: A Catalyst for Change You're probably wondering what's really happening when a couple like Hassan and Nazie Nemazee put their name on a legal fellowship. Skipping the melodrama, it's all about making a dent in the criminal justice system. These two aren't just slapping their name on a plaque—they're throwing real support behind actions that matter....

Continue Reading
Havertys Dividend: A Steady Payout Tradition Continues

Updated Category News Views 163

Another Year, Another Dividend for Havertys Man, talk about a company with a rock-solid habit. Havertys Furniture Companies (NYSE: HVT) just announced its latest cash dividend, cementing a tradition that's been rolling since 1935. They're dropping $0.33 per share on the common stock and $0.31 on the Class A common stock. It's set to hit investors' pockets by December 9,...

Continue Reading
IRTC Faces Investigation: Shares Plunge Amid Uncertainty

Updated Category News Views 63

Securities Trouble on the Horizon: IRTC Takes a Hit Wake up and adjust your seat, folks—iRhythm Technologies (NASDAQ:IRTC) is in the spotlight, and it ain't pretty. Shares nosedived over 30% in a single morning, stirring up quite the murky waters for shareholders. The trigger? A less-than-stellar third-quarter report. The Numbers Don't Lie—Or Do They? Management...

Continue Reading

Top 5 Most Recently Viewed Articles

Apertura Gene Therapy Collaborates on Prion Disease Treatment

Updated Category News Views 123

Apertura Gene Therapy Teams Up with Broad Institute Apertura Gene Therapy, a leading biotechnology firm committed to pioneering solutions in gene therapy, is collaborating with the Broad Institute, which is renowned for its groundbreaking research initiatives. The project aims to advance the development of a novel gene therapy targeting prion disease using an engineered...

Continue Reading
Bausch & Lomb Exceeds Expectations with Strong Q3 Growth

Updated Category News Views 67

Bausch & Lomb Achieves Impressive Third Quarter Results Bausch & Lomb Corp. (NYSE:BLCO) has recently captured attention in the financial markets after delivering strong third-quarter results for 2024. H.C. Wainwright, a prominent investment firm, revised the stock price target upward to $23.00 from the previous $22.00 while maintaining a Buy rating on the stock. This...

Continue Reading
Experience Winter Delights with BIGGBY® COFFEE's TWIX® Treats

Updated Category News Views 141

Discover the Seasonal Magic of BIGGBY® COFFEE The new limited-time winter offerings from BIGGBY® COFFEE are designed to delight cocoa and coffee lovers alike. This season, fans can indulge in a unique Salted Caramel lineup inspired by TWIX® candy. These festive beverages are available from early January through late February, providing a decadent way to enjoy the...

Continue Reading
Borr Drilling Limited's New Offering: What Investors Should Know

Updated Category News Views 229

Borr Drilling Limited Plans Significant Share Offering Borr Drilling Limited (NYSE: BORR) has recently announced plans to conduct a public offering of its common shares, intending to raise approximately $85 million in gross proceeds. The company aims to offer around 21 million shares in this equity initiative, reflecting its commitment to continued growth and investment...

Continue Reading